All In Biotech

Drug Trial Radar · NCT05618314

Study of AT-527 in Subjects With Normal and Impaired Renal Function

A Phase 1, Open-Label, Parallel-Group, Single-Dose Adaptive Study to Evaluate the Safety and Pharmacokinetics of AT-527 in Adult Subjects With Normal and Impaired Renal Function Sub-Study: Effects of Probenecid on the Pharmacokinetics of AT-527 in Healthy Adult Subjects

Last checked: Nov 20, 2026Latest source record: Jul 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Oct 17, 2022

Primary completion

Jun 15, 2024

Study completion Jun 15, 2024

Sponsor

Lead sponsor
Atea Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Nov 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Study of AT-527 in Subjects with Normal and Impaired Renal Function

Conditions

  • Healthy Volunteer
  • Renal Impairment

Interventions

  • AT-527Drug

    single dose AT-527

  • AT-527Drug

    Single dose of AT-527 pre- and post-dialysis

  • AT-527 and ProbenecidDrug

    Single dose of AT-527 on Days 1 and 15. Probenecid administered twice daily (BID) Days 14-19

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK) of AT-527 Maximum plasma concentration (Cmax)Time frame: Day 1
  2. Pharmacokinetics (PK) of AT-527 Area under the plasma concentration-time curve (AUC)Time frame: Day 1
  3. Pharmacokinetics (PK) of AT-527 AUCTime frame: Day 1

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Atea Study Site

    Québec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.